Merge Communications

Creativity in patient recruitment. Uncovering patient truths. Making study teams happy campers. Those are a few of our favorite things.

[Merge Communications @MergeComm]

“Behavioral science...[addresses challenges in clinical trials] not as isolated operational problems, but as predictable consequences of [trial design, site selection & patient engagement]”

@Clin_Trials proposes using human psych in trials here: https://t.co/olQn4jAiSG

[Merge Communications @MergeComm]

Merge needed Alzheimer’s patients and caregivers to “take note of our study” in 30 countries. Read case study.

https://t.co/auarFfp8Au

[Merge Communications @MergeComm]

F. Sandoval knows that true patient engagement is built through community presence, cultural fluency & outreach before a study launches. The real secret to strong recruitment is understanding both the science and the audience. Read about his mission here: https://t.co/bAmfHJaeqp

[Merge Communications @MergeComm]

Right-Sized Recruiting from Merge Clinical Study Communications is a customized campaign option ideal for medium to large studies.

https://t.co/auarFfp8Au

[Merge Communications @MergeComm]

Merge Clinical Study Communications speeds relief to sites – accelerating timelines and maximizing budgets.

https://t.co/KC56ZjoOKU

[Merge Communications @MergeComm]

When it comes to diversity, sponsors know who they need to reach. The real kicker is knowing how to reach those communities. Start by investing in leadership that will make smarter site selections, localize outreach & cultivate real community partnership.

https://t.co/uCZbPC7krf

[Merge Communications @MergeComm]

“True heroism is remarkably sober, very undramatic. It is not the urge to surpass all others at whatever cost, but the urge to serve others at whatever cost.” — Arthur Ashe #HappyMemorialDay 🇺🇸 🎖️ 💙

[Merge Communications @MergeComm]

Merge Clinical Study Communications developed a highly effective tool for reporting pre-identified patients – in under 6 weeks, in 38 countries, with no technical issues. Learn more.

https://t.co/auarFfp8Au

[Merge Communications @MergeComm]

Trial patients enduring their disease & encountering trial barriers is “a national problem [that] requires a local solution,” says M. Fenton, CEO. Fenton found that when community trust was prioritized, underrepresented groups were more engaged in trials.

https://t.co/S3FYQ3owcM

[Merge Communications @MergeComm]

DCTs promised faster timelines, wider access & low costs. However, a recent study shows DCTs haven’t delivered results the way many anticipated, which has caused industry interest to decline. In 2022, the use of DCTs nearly returned to pre-pandemic levels.
https://t.co/sdedr2t91w

[Merge Communications @MergeComm]

Keep your study top-of-mind with all study stakeholders. Learn more about Brandbuilder – from Merge Clinical Study Communications.

https://t.co/auarFfp8Au

[Merge Communications @MergeComm]

This #NationalVolunteerWeek, we celebrate the clinical trial volunteers who play a vital role in advancing medical research and bringing new treatments to life. Thank you for being the heart of progress! 🧪🫶🏼🔎

[Merge Communications @MergeComm]

The FDA issued a guide on how clinical trials can enroll more underrepresented patients, mainly by broadening I/E criteria to embody a more inclusive sample pool. Underrepresentation must be challenged to produce viable evidence & relevance going forward. https://t.co/K7fNYNOVji

[Merge Communications @MergeComm]

Merge Clinical Study Communications excels at media strategy, planning and placement – in traditional media – and in online, mobile and social media – nationally, and globally.

https://t.co/auarFfp8Au

[Merge Communications @MergeComm]

Merge Clinical Study Communications is known for creating messages that stand apart from the ordinary – in every therapeutic area.

https://t.co/auarFfp8Au

[Merge Communications @MergeComm]

~95% of rare diseases have 0 approved treatment options, meaning trials are usually the only treatment available for these patients. R. Davi, a VP @Medidata, wants to increase tech use in rare disease trials to improve timelines, experiences & outcomes.

https://t.co/cmt3YpbOiY

[Merge Communications @MergeComm]

This #WorldHealthDay, we recognize the power of clinical trials in shaping the future of medicine. Every trial brings us closer to safer, more effective treatments for patients everywhere.💙🍎🌍

[Merge Communications @MergeComm]

It’s #NationalDoctorsDay! To all the physicians and clinical researchers, thank you for your long hours, your expertise, and the difference you make in so many lives. 🩺 💙🥼

[Merge Communications @MergeComm]

Happy #EmployeeAppreciationDay!🎉 Your dedication to teamwork doesn’t just drive success-- it shapes our culture & inspires us every day. Thank you for the passion you bring, the challenges you conquer & the excellence you deliver. We couldn’t do it without you.

[Merge Communications @MergeComm]

#RareDiseaseDay aims to raise awareness for conditions that affect over 300 million people worldwide, many of whom face delayed diagnoses, limited treatment options & daily challenges that often go unseen. Support research that leads to earlier diagnosis & improved QOL.